시장보고서
상품코드
1270833

세계의 신경혈관 기기 시장 : 질환 병리별(뇌동맥류(색전코일), 허혈성 뇌졸중(혈전제거, 흡인, 미세 카테터), AVM(액체색전물질)), 최종사용자(병원), 지역별 예측(-2028년)

Neurovascular Devices Market by Disease Pathology (Cerebral Ameurysm (Embolic coils), Ischemic Stroke (Clot retrievers, Aspiration, Microcatheters), AVM (Liquid Embolic Agents), End User (Hospitals), & Region - Global Forecast to 2028

발행일: | 리서치사: MarketsandMarkets | 페이지 정보: 영문 255 Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 신경혈관 기기(neurovascular device) 시장 규모는 2023년 36억 달러에서 2028년까지 55억 달러에 달할 것으로 예상되며, 예측 기간 동안 8.7%의 CAGR을 나타낼 것으로 전망됩니다.

신경혈관 기기수요 증가는 고혈압, 당뇨병, 비만 증가로 허혈성 뇌졸중, 뇌동맥류와 같은 다양한 신경혈관 질환의 발병 위험에 노출된 인구 비율이 증가함에 따라 발생합니다. 그러나 신경중재수술 및 관련 제품의 높은 비용과 신흥국의 숙련된 신경과 의사의 부족은 시장 성장에 걸림돌이 될 것으로 보입니다.

"예측 기간 동안 허혈성 뇌졸중 부문이 가장 높은 CAGR을 차지할 것"

질병 병리별로 신경혈관 기기 시장은 뇌동맥류, 허혈성 뇌졸중, 경동맥 협착, 동정맥 기형(AVM) 및 동정맥 누공, 기타(해면상 혈관 기형, 모야모야병 등)로 구분됩니다. 허혈성 뇌졸중 부문은 허혈성 뇌졸중 발생률 증가와 기계적 혈전제거술 증가로 인해 더 높은 CAGR로 성장할 것으로 예상됩니다.

"예측 기간 동안 최종 사용자별 신경외과 기기 시장에서 병원 및 수술센터 부문이 가장 큰 시장 점유율을 차지할 것으로 예상된다"

최종 사용자별로 신경혈관 기기 시장은 병원 및 수술센터, 외래 진료 센터, 연구소 및 학술 기관으로 분류됩니다. 병원 및 수술센터는 대상 환자의 입원 증가, 신경혈관 수술 증가, 신흥 시장에서의 병원 인프라 구축, 그리고 이러한 환경에서 최첨단 신경혈관 치료 장비를 사용할 수 있기 때문에 예측 기간 동안 신경혈관 기기 시장에서 가장 큰 점유율을 차지할 것으로 예상됩니다.

"예측 기간 동안 지역별 신경외과 기기 시장에서 가장 높은 시장 점유율을 차지하는 지역은 북미가 될 것"

지역별로 보면, 세계 신경외과 기기 시장은 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 분류됩니다. 북미는 예측 기간 동안 높은 시장 점유율을 차지할 것으로 예상됩니다. 이는 허혈성 뇌졸중, 뇌동맥류, 동정맥 기형(AVM)에 대한 혈관 내 치료법의 보급, 새로운 신경혈관 기기 개발을 위한 R&D 투자의 잠재력, 이 지역의 주요 기업들의 강력한 입지, 신경혈관 치료법에 대한 유리한 상환 정책 등의 요인에 기인한 것으로 보입니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 프리미엄 인사이트

제5장 시장 개요

  • 서론
  • 시장 역학
    • 성장 촉진요인
    • 성장 억제요인
    • 기회
    • 과제
  • 공급망 분석
  • 밸류체인 분석
  • Porter의 Five Forces 분석
  • 규제 상황
  • 상환 시나리오
  • 가격 동향 분석
  • 특허 분석
  • 무역 분석
  • 에코시스템 맵
  • 사례 연구 분석
  • 주요 컨퍼런스 및 이벤트(2022년-2023년)
  • 이해관계자와 구입 기준
  • 주요 구입 기준

제6장 신경혈관 기기 시장 : 질환 병리별

  • 서론
  • 뇌동맥류
    • 색전코일
    • 혈류 전환 기기
    • 두개내 스텐트
    • 마이크로카테터
    • 가이드와이어
  • 허혈성 뇌졸중
    • 혈전 회수 디바이스
    • 흡인 기기
    • 혈관 스네어
    • 마이크로카테터
    • 마이크로가이드와이어
    • 풍선 카테터
  • 경동맥 협착증
    • 경동맥 스텐트
    • 색전 방지 기기
    • 풍선 카테터
  • 동정맥기형(AVM) 및 동정맥루
    • 액체 색전물질
    • 폐쇄 풍선 카테터
    • 마이크로카테터
  • 기타

제7장 신경혈관 기기 시장 : 최종사용자별

  • 서론
  • 병원 및 수술센터
  • 외래치료센터
  • 연구소 및 학술기관

제8장 신경혈관 기기 시장 : 지역별

  • 서론
  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 프랑스
    • 영국
    • 이탈리아
    • 스페인
    • 기타 유럽
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 호주
    • 한국
    • 기타 아시아태평양
  • 라틴아메리카
    • 브라질
    • 멕시코
    • 기타 라틴아메리카
  • 중동 및 아프리카

제9장 경쟁 구도

  • 서론
  • 매출 점유율 분석
  • 시장 점유율 분석
  • 경쟁 리더십 매핑 : 기업 평가 상한(2022년)
  • 경쟁 리더십 매핑 : 스타트업/중소기업 평가 상한(2022년)
  • 신경혈관 기기 시장 : 주요 기업 실적 분석

제10장 기업 개요

  • 주요 기업
    • STRYKER
    • MEDTRONIC
    • JOHNSON & JOHNSON
    • TERUMO CORPORATION
    • PENUMBRA, INC.
    • MICROPORT SCIENTIFIC CORPORATION
    • BALT
    • KANEKA CORPORATION
    • PHENOX GMBH
    • ASAHI INTECC CO., LTD
    • PERFLOW MEDICAL LTD.
    • RAPID MEDICAL
    • CERUS ENDOVASCULAR INC.
    • ACANDIS GMBH
    • EVASC
    • SENSOME
    • LEPU MEDICAL TECHNOLOGY(BEIJING) CO., LTD.
    • IMPERATIVE CARE
    • MEDIKIT CO., LTD.
    • ZYLOX-TONBRIDGE MEDICAL CO., LTD.
  • 기타 기업
    • SILK ROAD MEDICAL, INC.
    • ARTIO MEDICAL, INC.
    • IVASCULAR
    • OXFORDENDOVASCULAR
    • NEUROVASC TECHNOLOGIES, INC.

제11장 부록

LSH 23.05.24

The global neurovascular devices market is projected to reach USD 5.5 Billion by 2028 from USD 3.6 Billion in 2023, at a CAGR of 8.7% during the forecast period. The increase in the demand for neurovascular devices market is driven by the increasing population proportion at a risk of developing various neurovascular diseases such as Ischemic stroke, cerebral aneurysms owing to the growing prevalence of hypertension, diabetes, and obesity. However, high cost of neuro-interventional procedures and associated products and shortage of skilled neurologists across emerging countries are likely to hamper the growth of market.

"Ischemic stroke segment accounted for the highest CAGR during the forecast period"

Based on disease pathology, the neurovascular devices market is segmented into cerebral aneurysm, ischemic strokes, carotid artery stenosis, arteriovenous malformations & fistulas, and other disease pathologies (includes cavernous malformations and moyamoya disease). The ischemic stroke segment to grow a at a higher CAGR owing to increasing incidence of ischemic stroke and increase in the mechanical thrombectomy procedures.

"The Hospitals & surgical centers segment accounted for the largest market share in the neurovascular devices market, by end user, during the forecast period"

Based on end user, the neurovascular devices market is segmented into hospitals & surgical centers, ambulatory care centers, and research laboratories and academic institutes. The hospital & surgical centers captured the largest share of neurovascular devices market during the forecast period attributed to the increasing hospitalization of target patient population, rising volume of neurovascular surgeries, and upgradation in the infrastructure of hospitals in developing nations along with the availability of technological advance neurovascular treatment devices in these settings.

"The North America segment accounted for the highest market share in the neurovascular devices market, by region, during the forecast period"

Based on the region, the global neurovascular devices market is categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to witness a high market share during the forecast period. This can be attributed to the factors such as strong adoption of endovascular treatment procedures for the ischemic stroke, cerebral aneurysm, and arteriovenous malformation, availability of R& D investments for development of novel neurovascular devices, strong foothold of key players in region, and favorable reimbursement policy for neurovascular treatment procedures.

Breakdown of supply-side primary interviews, by company type, designation, and region:

  • By Company Type: Tier 1 (30%), Tier 2 (45%), and Tier 3 (25%)
  • By Designation: C-level (20%), Director-level (20%), and Others (45%)
  • By Region: North America (40%), Asia- Pacific (30%), Europe (20%), Latin America (7%) and Middle East & Africa(3%)

Prominent companies include Stryker (US), Johnson & Johnson (US), Medtronic (Ireland), Terumo Corporation (Japan), Penumbra, Inc. (US), MicroPort Scientific Corporation (China), Kaneka Corporation (Japan), BALT (France), Perflow Medical Ltd. (Israel), Phenox GmbH (Germany), Sensome (France), Evasc (Canada), Rapid Medical (Israel), Asahi Intecc Co., Ltd (Japan), Acandis GmbH (Germany), Medikit Co. Ltd. (Japan), Imperative Care (US), Lepu Medical Technology(Beijing)Co., Ltd. (China), Cerus Endovascular Inc. (USA), and Zylox-Tonbridge Medical Co., Ltd (China)

Research Coverage

This research report categorizes the neurovascular devices market by disease pathology (cerebral aneurysm, ischemic strokes, carotid artery stenosis, arteriovenous malformations & fistulas, and other disease pathologies), by end user (hospitals & surgical centers, ambulatory care centers, and research laboratories and academic institutes), and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the neurovascular devices market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements. new product & service launches, mergers and acquisitions, and recent developments associated with the neurovascular devices market. Competitive analysis of upcoming startups in the neurovascular devices market ecosystem is covered in this report.

Key Benefits of Buying the Report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall neurovascular devices market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

  • Analysis of key drivers (rising incidence of neurovascular diseases, increasing neurovascular procedures, availability of medical reimbursement, and expansion of healthcare infrastructure across emerging nations), restraints (high neurovascular procedural & related devices cost and shortage of skilled neurosurgeon in emerging countries ), opportunities (increase in the preference of minimally invasive neurosurgical procedures and rising R& D activities in neurovascular therapies), and challenges (stringent regulatory approval process for neurovascular treatment devices) influencing the growth of the neurovascular devices market
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the neurovascular devices market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the neurovascular devices market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the neurovascular devices market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Stryker (US), Johnson & Johnson (US), Medtronic (Ireland), Terumo Corporation (Japan), Penumbra, Inc. (US), MicroPort Scientific Corporation (China), among others in the neurovascular devices market strategies.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 GEOGRAPHIC SCOPE
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 MARKET STAKEHOLDERS
  • 1.6 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY RESEARCH
      • 2.1.2.1 Key data from primary sources
    • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
    • FIGURE 3 NEUROVASCULAR DEVICES MARKET: BREAKDOWN OF PRIMARIES
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
    • 2.2.1 PRODUCT-BASED MARKET ESTIMATION
    • 2.2.2 VOLUME-BASED MARKET ESTIMATION
    • FIGURE 5 MARKET SIZE ESTIMATION: NEUROVASCULAR DEVICES MARKET
    • 2.2.3 PRIMARY RESEARCH VALIDATION
  • 2.3 DATA TRIANGULATION
    • FIGURE 6 DATA TRIANGULATION METHODOLOGY
  • 2.4 RESEARCH ASSUMPTIONS AND LIMITATIONS
    • 2.4.1 RESEARCH ASSUMPTIONS
    • 2.4.2 RESEARCH LIMITATIONS
  • 2.5 RECESSION IMPACT
    • TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2021-2027 (% GROWTH)

3 EXECUTIVE SUMMARY

    • FIGURE 7 NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023 VS. 2028 (USD MILLION)
    • FIGURE 8 HOSPITALS AND SURGICAL CENTERS SEGMENT TO CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD
    • FIGURE 9 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN NEUROVASCULAR DEVICES MARKET DURING FORECAST PERIOD

4 PREMIUM INSIGHTS

  • 4.1 NEUROVASCULAR DEVICES MARKET OVERVIEW
    • FIGURE 10 AN INCREASE IN THE NUMBER OF DISEASES RELATED TO NEUROLOGICAL DISORDERS SUCH AS BRAIN/ CEREBRAL ANEURYSMS, STROKES, AND EPILEPSY, IS EXPECTED TO DRIVE THE MARKET GROWTH.
  • 4.2 NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2023 VS. 2028 (USD MILLION)
    • FIGURE 11 CEREBRAL ANEURYSMS TO DOMINATE NEUROVASCULAR DEVICES MARKET DURING FORECAST PERIOD
  • 4.3 NEUROVASCULAR DEVICES MARKET, BY REGION AND DISEASE PATHOLOGY (2022)
    • FIGURE 12 CEREBRAL ANEURYSMS SEGMENT ACCOUNTED FOR HIGHEST MARKET SHARE IN US
  • 4.4 NEUROVASCULAR DEVICES MARKET, BY COUNTRY
    • FIGURE 13 CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 14 NEUROVASCULAR DEVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising incidence of neurovascular diseases
    • FIGURE 15 PROPORTION OF GERIATRIC TO TOTAL WORLD POPULATION, BY COUNTRY, 2020 VS. 2030 (MILLION PEOPLE)
      • 5.2.1.2 Availability of medical reimbursements for neurovascular procedures
    • TABLE 2 US: REIMBURSEMENT FOR INTERVENTIONAL NEUROLOGY PROCEDURES
      • 5.2.1.3 Expansion of healthcare infrastructure across emerging economies
      • 5.2.1.4 Rising demand for effective neurovascular therapies
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Shortage of skilled neurosurgeons
      • 5.2.2.2 High procedural cost of neurovascular surgeries and associated products
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Rising R&D activities for neurovascular therapies
      • 5.2.3.2 Growing preference for minimally invasive neurosurgical procedures
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Stringent regulatory approval process for medical devices
  • 5.3 SUPPLY CHAIN ANALYSIS
    • FIGURE 16 NEUROVASCULAR DEVICES MARKET: SUPPLY CHAIN ANALYSIS
  • 5.4 VALUE CHAIN ANALYSIS
    • FIGURE 17 VALUE CHAIN ANALYSIS: MAXIMUM VALUE ADDED THROUGH REGULATION & DISTRIBUTION STAGES
  • 5.5 PORTER'S FIVE FORCES ANALYSIS
    • 5.5.1 OVERVIEW
    • TABLE 3 NEUROVASCULAR DEVICES MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.5.2 THREAT OF NEW ENTRANTS
    • 5.5.3 THREAT OF SUBSTITUTES
    • 5.5.4 BARGAINING POWER OF SUPPLIERS
    • 5.5.5 BARGAINING POWER OF BUYERS
    • 5.5.6 INTENSITY OF COMPETITIVE RIVALRY
  • 5.6 REGULATORY LANDSCAPE
    • 5.6.1 NORTH AMERICA
      • 5.6.1.1 US
    • TABLE 4 US FDA: MEDICAL DEVICE CLASSIFICATION
    • TABLE 5 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
      • 5.6.1.2 Canada
    • 5.6.2 EUROPE
    • 5.6.3 ASIA PACIFIC
      • 5.6.3.1 China
      • 5.6.3.2 Japan
      • 5.6.3.3 India
      • 5.6.3.4 South Korea
  • 5.7 REIMBURSEMENT SCENARIO
    • TABLE 6 REIMBURSEMENT CODES FOR VARIOUS PROCEDURES (2021)
  • 5.8 PRICING TREND ANALYSIS
    • 5.8.1 AVERAGE SELLING PRICE OF NEUROVASCULAR DEVICES, BY KEY PLAYER, 2021 (USD)
    • 5.8.2 AVERAGE SELLING PRICE OF NEUROVASCULAR DEVICES, BY REGION/COUNTRY, 2021 (USD)
  • 5.9 PATENT ANALYSIS
    • FIGURE 18 TOP PATENT APPLICANTS FOR ORTHOPEDIC DEVICES, JANUARY 2012-MARCH 2023
  • 5.10 TRADE ANALYSIS
    • TABLE 7 IMPORT DATA FOR HS CODE 901890, BY COUNTRY, 2017-2021 (USD MILLION)
    • TABLE 8 EXPORT DATA FOR HS CODE 901890, BY COUNTRY, 2016-2020 (USD MILLION)
  • 5.11 ECOSYSTEM MAP
  • 5.12 CASE STUDY ANALYSIS
    • 5.12.1 STENT-ASSISTED COILING (SAC) THERAPY FOR INTRACRANIAL ANEURYSMS
    • TABLE 9 USAGE OF INTRACRANIAL STENTS FOR TREATMENT OF BROAD-NECKED INTRACRANIAL ANEURYSMS
  • 5.13 KEY CONFERENCES AND EVENTS IN 2022-2023
    • TABLE 10 NEUROVASCULAR DEVICES MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
    • FIGURE 19 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.14 STAKEHOLDERS AND BUYING CRITERIA
    • 5.14.1 KEY STAKEHOLDERS
    • FIGURE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR KEY APPLICATIONS
    • TABLE 11 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR KEY APPLICATION SEGMENTS (%)
  • 5.15 KEY BUYING CRITERIA
    • FIGURE 21 KEY BUYING CRITERIA FOR NEUROVASCULAR DEVICES
    • TABLE 12 KEY BUYING CRITERIA FOR NEUROVASCULAR DEVICES

6 NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY

  • 6.1 INTRODUCTION
    • TABLE 13 NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 14 NEUROVASCULAR DEVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 15 NEUROVASCULAR DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 6.2 CEREBRAL ANEURYSMS
    • TABLE 16 NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 17 NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 18 NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY END USER, 2021-2028 (USD MILLION)
    • 6.2.1 EMBOLIC COILS
    • TABLE 19 CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 20 CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
      • 6.2.1.1 Bare detachable coils
        • 6.2.1.1.1 Significant adoption of bare detachable coils by neurosurgeons for brain aneurysm treatment to promote growth
    • TABLE 21 CEREBRAL ANEURYSMS MARKET FOR BARE DETACHABLE COILS, BY REGION, 2021-2028 (USD MILLION)
      • 6.2.1.2 Coated detachable coils
        • 6.2.1.2.1 High cost of coated detachable coils to limit adoption
    • TABLE 22 CEREBRAL ANEURYSMS MARKET FOR COATED DETACHABLE COILS, BY REGION, 2021-2028 (USD MILLION)
    • 6.2.2 FLOW DIVERSION DEVICES
      • 6.2.2.1 Rising R&D activities to develop novel flow diversion devices to promote growth
    • TABLE 23 CEREBRAL ANEURYSMS MARKET FOR FLOW DIVERSION DEVICES, BY REGION, 2021-2028 (USD MILLION)
    • 6.2.3 INTRACRANIAL STENTS
      • 6.2.3.1 Increased efficacy of stent-assisted coiling for treatment of wide-necked intracranial aneurysms to boost adoption
    • TABLE 24 CEREBRAL ANEURYSMS MARKET FOR INTRACRANIAL STENTS, BY REGION, 2021-2028 (USD MILLION)
    • 6.2.4 MICROCATHETERS
      • 6.2.4.1 Growing number of neurovascular procedures and favorable reimbursement scenarios to boost demand
    • TABLE 25 CEREBRAL ANEURYSMS MARKET FOR MICROCATHETERS, BY REGION, 2021-2028 (USD MILLION)
    • 6.2.5 GUIDEWIRES
      • 6.2.5.1 Growing utilization of nitinol guidewires for cerebral aneurysm procedures to boost growth
    • TABLE 26 CEREBRAL ANEURYSMS MARKET FOR GUIDEWIRES, BY REGION, 2021-2028 (USD MILLION)
  • 6.3 ISCHEMIC STROKES
    • TABLE 27 NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKE, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 28 NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKE, BY TYPE 2021-2028 (USD MILLION)
    • TABLE 29 NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKE, BY END USER, 2021-2028 (USD MILLION
    • 6.3.1 CLOT RETRIEVER DEVICES
      • 6.3.1.1 Growing number of clinical trials for development of novel clot retriever stents to drive market
    • TABLE 30 ISCHEMIC STROKES MARKET FOR CLOT RETRIEVER DEVICES, BY REGION, 2021-2028 (USD MILLION)
    • 6.3.2 SUCTION & ASPIRATION DEVICES
      • 6.3.2.1 Rapid commercialization of technologically advanced aspiration devices for ischemic stroke treatment to support market
    • TABLE 31 ISCHEMIC STROKES MARKET FOR SUCTION & ASPIRATION DEVICES, BY REGION, 2021-2028 (USD MILLION)
    • 6.3.3 VASCULAR SNARES
      • 6.3.3.1 Limited procedural benefits in stroke treatment to limit adoption of vascular snares
    • TABLE 32 ISCHEMIC STROKES MARKET FOR VASCULAR SNARES, BY REGION, 2021-2028 (USD MILLION)
    • 6.3.4 MICROCATHETERS
      • 6.3.4.1 High demand for minimally invasive treatment in ischemic strokes to boost adoption of microcatheters
    • TABLE 33 ISCHEMIC STROKES MARKET FOR MICROCATHETERS, BY REGION, 2021-2028 (USD MILLION)
    • 6.3.5 MICROGUIDEWIRES
      • 6.3.5.1 Increasing innovations in guidewires to promote growth
    • TABLE 34 ISCHEMIC STROKES MARKET FOR MICROGUIDEWIRES, BY REGION, 2021-2028 (USD MILLION)
    • 6.3.6 BALLOON CATHETERS
      • 6.3.6.1 Growing recognition of benefits associated with balloon catheters to bolster demand
    • TABLE 35 ISCHEMIC STROKES MARKET FOR BALLOON CATHETERS, BY REGION, 2021-2028 (USD MILLION)
  • 6.4 CAROTID ARTERY STENOSIS
    • TABLE 36 NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS CAROTID ARTERY STENOSIS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 37 NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 38 NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY END USER, 2021-2028 (USD MILLION)
    • 6.4.1 CAROTID ARTERY STENTS
      • 6.4.1.1 Growing adoption of carotid artery stents for carotid intervention procedures to support growth
    • TABLE 39 CAROTID ARTERY STENOSIS MARKET FOR CAROTID ARTERY STENTS, BY REGION, 2021-2028 (USD MILLION)
    • 6.4.2 EMBOLIC PROTECTION DEVICES
      • 6.4.2.1 Growing utilization of distal filters during carotid intervention procedures to promote growth
    • TABLE 40 CAROTID ARTERY STENOSIS MARKET FOR EMBOLIC PROTECTION DEVICES, BY REGION, 2021-2028 (USD MILLION)
    • 6.4.3 BALLOON CATHETERS
      • 6.4.3.1 Growing preference for balloon catheters to improve efficacy of carotid intervention procedures to augment growth
    • TABLE 41 CAROTID ARTERY STENOSIS MARKET FOR BALLOON CATHETERS, BY REGION, 2021-2028 (USD MILLION)
  • 6.5 ARTERIOVENOUS MALFORMATION & FISTULAS
    • TABLE 42 NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATION & FISTULAS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 43 NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATION & FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 44 NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATION & FISTULAS, BY END USER, 2021-2028 (USD MILLION)
    • 6.5.1 LIQUID EMBOLIC AGENTS
      • 6.5.1.1 Development of novel liquid embolic agents offering high embolization of arteriovenous fistulas to support growth
    • TABLE 45 ARTERIOVENOUS MALFORMATION & FISTULAS MARKET FOR LIQUID EMBOLIC AGENTS, BY REGION, 2021-2028 (USD MILLION)
    • 6.5.2 OCCLUSION BALLOON CATHETERS
      • 6.5.2.1 Growing utilization of balloon catheters for AVM treatment to support growth
    • TABLE 46 ARTERIOVENOUS MALFORMATION & FISTULAS MARKET FOR OCCLUSION BALLOON CATHETERS, BY REGION, 2021-2028 (USD MILLION)
    • 6.5.3 MICROCATHETERS
      • 6.5.3.1 Improved compatibility of microcatheters with embolic agents to boost demand
    • TABLE 47 ARTERIOVENOUS MALFORMATION & FISTULAS MARKET FOR MICROCATHETERS, BY REGION, 2021-2028 (USD MILLION)
  • 6.6 OTHER DISEASE PATHOLOGIES
    • TABLE 48 NEUROVASCULAR DEVICES MARKET FOR OTHER DISEASE PATHOLOGIES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 49 NEUROVASCULAR DEVICES MARKET FOR OTHER DISEASE PATHOLOGIES, BY END USER, 2021-2028 (USD MILLION)

7 NEUROVASCULAR DEVICES MARKET, BY END USER

  • 7.1 INTRODUCTION
    • TABLE 50 NEUROVASCULAR DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 7.2 HOSPITALS AND SURGICAL CENTERS
    • 7.2.1 INCREASING VOLUME OF NEUROVASCULAR PROCEDURES DUE TO AVAILABILITY OF ADVANCED EQUIPMENT TO DRIVE MARKET
    • TABLE 51 NEUROVASCULAR DEVICES MARKET FOR HOSPITALS AND SURGICAL CENTERS, BY REGION, 2021-2028 (USD MILLION)
  • 7.3 AMBULATORY CARE CENTERS
    • 7.3.1 OPERATIONAL AND ECONOMIC BENEFITS OFFERED BY ACCS TO DRIVE MARKET
    • TABLE 52 NEUROVASCULAR DEVICES MARKET FOR AMBULATORY CARE CENTERS, BY REGION, 2021-2028 (USD MILLION)
  • 7.4 RESEARCH LABORATORIES AND ACADEMIC INSTITUTES
    • 7.4.1 INCREASING COLLABORATIONS FOR DEVELOPMENT OF TECHNOLOGICALLY ADVANCED NEUROVASCULAR DEVICES TO SUPPORT MARKET GROWTH
    • TABLE 53 NEUROVASCULAR DEVICES MARKET FOR RESEARCH LABORATORIES AND ACADEMIC INSTITUTES, BY REGION, 2021-2028 (USD MILLION)

8 NEUROVASCULAR DEVICES MARKET, BY REGION

  • 8.1 INTRODUCTION
    • TABLE 54 NEUROVASCULAR DEVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 8.2 NORTH AMERICA
    • 8.2.1 NORTH AMERICA: RECESSION IMPACT
    • FIGURE 22 NEUROVASCULAR DEVICES MARKET: NORTH AMERICA SNAPSHOT
    • TABLE 55 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 56 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 57 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 58 NORTH AMERICA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 59 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 60 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 61 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 62 NORTH AMERICA: NEUROVASCULAR DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 8.2.2 US
      • 8.2.2.1 Presence of established neurovascular device manufacturers to drive market
    • TABLE 63 US: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 64 US: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 65 US: EMBOLIC COILS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 66 US: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 67 US: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 68 US: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • 8.2.3 CANADA
      • 8.2.3.1 Large target pool for ischemic stroke patients to drive market
    • TABLE 69 CANADA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 70 CANADA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 71 CANADA: EMBOLIC COILS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 72 CANADA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 73 CANADA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 74 CANADA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
  • 8.3 EUROPE
    • 8.3.1 EUROPE: RECESSION IMPACT
    • TABLE 75 EUROPE: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 76 EUROPE: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 77 EUROPE: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 78 EUROPE: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 79 EUROPE: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 80 EUROPE: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 81 EUROPE: NEUROVASCULAR DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 8.3.2 GERMANY
      • 8.3.2.1 Increasing adoption of endovascular coils and stents to drive market
    • TABLE 82 GERMANY: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 83 GERMANY: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 84 GERMANY: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 85 GERMANY: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 86 GERMANY: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 87 GERMANY: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • 8.3.3 FRANCE
      • 8.3.3.1 Growing preference for minimally invasive neurovascular procedures to drive market
    • TABLE 88 FRANCE: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 89 FRANCE: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 90 FRANCE: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 91 FRANCE: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKE, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 92 FRANCE: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 93 FRANCE: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • 8.3.4 UK
      • 8.3.4.1 Rising government initiatives to increase accessibility of neurovascular procedures to drive market
    • TABLE 94 UK: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 95 UK: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 96 UK: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 97 UK: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 98 UK: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 99 UK: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • 8.3.5 ITALY
      • 8.3.5.1 Increasing thrombectomy treatment rates to drive demand for neurovascular devices
    • TABLE 100 ITALY: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 101 ITALY: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 102 ITALY: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 103 ITALY: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 104 ITALY: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 105 ITALY: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • 8.3.6 SPAIN
      • 8.3.6.1 Rising number of clinical trials for interventional neurovascular procedures to support market growth
    • TABLE 106 SPAIN: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 107 SPAIN: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 108 SPAIN: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 109 SPAIN: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 110 SPAIN: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 111 SPAIN: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • 8.3.7 REST OF EUROPE
    • TABLE 112 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 113 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 114 REST OF EUROPE: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 115 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 116 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 117 REST OF EUROPE: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
  • 8.4 ASIA PACIFIC
    • 8.4.1 ASIA PACIFIC: RECESSION IMPACT
    • TABLE 118 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 119 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 120 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 121 ASIA PACIFIC: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 122 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 123 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 124 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 125 ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • FIGURE 23 NEUROVASCULAR DEVICES MARKET: ASIA PACIFIC SNAPSHOT
    • 8.4.2 JAPAN
      • 8.4.2.1 Favorable reimbursement policy for adoption of neurovascular procedures to drive market
    • TABLE 126 JAPAN: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 127 JAPAN: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 128 JAPAN: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 129 JAPAN: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 130 JAPAN: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 131 JAPAN: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • 8.4.3 CHINA
      • 8.4.3.1 Robust presence of neurovascular device manufacturers to drive market
    • TABLE 132 CHINA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 133 CHINA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 134 CHINA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 135 CHINA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 136 CHINA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 137 CHINA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • 8.4.4 INDIA
      • 8.4.4.1 Supportive government initiatives to drive uptake for neurovascular devices
    • TABLE 138 INDIA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 139 INDIA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 140 INDIA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 141 INDIA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 142 INDIA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 143 INDIA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • 8.4.5 AUSTRALIA
      • 8.4.5.1 Rising incidence of cerebrovascular disease to drive market
    • TABLE 144 AUSTRALIA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 145 AUSTRALIA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 146 AUSTRALIA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 147 AUSTRALIA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 148 AUSTRALIA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 149 AUSTRALIA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • 8.4.6 SOUTH KOREA
      • 8.4.6.1 Health insurance coverage for neurovascular procedures to support market growth
    • TABLE 150 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 151 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 152 SOUTH KOREA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 153 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 154 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 155 SOUTH KOREA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • 8.4.7 REST OF ASIA PACIFIC
    • TABLE 156 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 157 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 158 REST OF ASIA PACIFIC: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 159 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 160 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 161 REST OF ASIA PACIFIC: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
  • 8.5 LATIN AMERICA
    • 8.5.1 LATIN AMERICA: RECESSION IMPACT
    • TABLE 162 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 163 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 164 LATIN AMERICA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 165 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 166 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 167 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 168 LATIN AMERICA: NEUROVASCULAR DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 8.5.2 BRAZIL
      • 8.5.2.1 Increasing awareness initiatives on stroke symptoms to drive market
    • TABLE 169 BRAZIL: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 170 BRAZIL: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 171 BRAZIL: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 172 BRAZIL: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 173 BRAZIL: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 174 BRAZIL: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • 8.5.3 MEXICO
      • 8.5.3.1 Increasing incidence of neurovascular diseases to support market growth
    • TABLE 175 MEXICO: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 176 MEXICO: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 177 MEXICO: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 178 MEXICO: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 179 MEXICO: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 180 MEXICO: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • 8.5.4 REST OF LATIN AMERICA
    • TABLE 181 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 182 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 183 REST OF LATIN AMERICA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 184 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 185 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 186 REST OF LATIN AMERICA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS AND FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
  • 8.6 MIDDLE EAST & AFRICA
    • 8.6.1 SHORTAGE OF NEUROSURGEONS AND POOR HEALTHCARE COVERAGE TO RESTRAIN MARKET GROWTH
    • 8.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
    • TABLE 187 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR CEREBRAL ANEURYSMS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 188 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2021-2028 (USD MILLION)
    • TABLE 189 MIDDLE EAST & AFRICA: CEREBRAL ANEURYSMS MARKET FOR EMBOLIC COILS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 190 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 191 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR CAROTID ARTERY STENOSIS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 192 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATIONS & FISTULAS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 193 MIDDLE EAST & AFRICA: NEUROVASCULAR DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)

9 COMPETITIVE LANDSCAPE

  • 9.1 INTRODUCTION
    • 9.1.1 STRATEGIES ADOPTED BY KEY PLAYERS
    • FIGURE 24 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS (2019-2023)
  • 9.2 REVENUE SHARE ANALYSIS
    • FIGURE 25 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN NEUROVASCULAR DEVICES MARKET
  • 9.3 MARKET SHARE ANALYSIS
    • FIGURE 26 NEUROVASCULAR DEVICES MARKET SHARE, BY KEY PLAYER (2022)
  • 9.4 COMPETITIVE LEADERSHIP MAPPING: COMPANY EVALUATION QUADRANT (2022)
    • 9.4.1 STARS
    • 9.4.2 EMERGING LEADERS
    • 9.4.3 PERVASIVE PLAYERS
    • 9.4.4 PARTICIPANTS
    • FIGURE 27 NEUROVASCULAR DEVICES MARKET: COMPETITIVE LEADERSHIP MAPPING FOR KEY PLAYERS (2021)
  • 9.5 COMPETITIVE LEADERSHIP MAPPING: STARTUPS/SME EVALUATION QUADRANT (2022)
    • 9.5.1 PROGRESSIVE COMPANIES
    • 9.5.2 RESPONSIVE COMPANIES
    • 9.5.3 DYNAMIC COMPANIES
    • 9.5.4 STARTING BLOCKS
    • FIGURE 28 NEUROVASCULAR DEVICES MARKET: COMPETITIVE LEADERSHIP MAPPING FOR SMES/STARTUPS (2022)
  • 9.6 NEUROVASCULAR DEVICES MARKET: FOOTPRINT ANALYSIS OF LEADING PLAYERS
    • TABLE 194 COMPANY FOOTPRINT ANALYSIS
    • TABLE 195 PRODUCT FOOTPRINT
    • TABLE 196 REGIONAL FOOTPRINT
    • 9.6.1 PRODUCT LAUNCHES & APPROVALS
    • TABLE 197 NEUROVASCULAR DEVICES MARKET: KEY PRODUCT LAUNCHES & APPROVALS (JANUARY 2019-MARCH 2023)
    • 9.6.2 DEALS
    • TABLE 198 NEUROVASCULAR DEVICES MARKET: KEY DEALS (JANUARY 2019-MARCH 2023)
    • 9.6.3 OTHER DEVELOPMENTS
    • TABLE 199 NEUROVASCULAR DEVICES MARKET: OTHER DEVELOPMENTS (JANUARY 2019-MARCH 2023)

10 COMPANY PROFILES

(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) **

  • 10.1 KEY PLAYERS
    • 10.1.1 STRYKER
    • TABLE 200 STRYKER: BUSINESS OVERVIEW
    • FIGURE 29 STRYKER: COMPANY SNAPSHOT (2022)
    • 10.1.2 MEDTRONIC
    • TABLE 201 MEDTRONIC: BUSINESS OVERVIEW
    • FIGURE 30 MEDTRONIC: COMPANY SNAPSHOT (2022)
    • 10.1.3 JOHNSON & JOHNSON
    • TABLE 202 JOHNSON & JOHNSON: BUSINESS OVERVIEW
    • FIGURE 31 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2022)
    • 10.1.4 TERUMO CORPORATION
    • TABLE 203 TERUMO CORPORATION: BUSINESS OVERVIEW
    • FIGURE 32 TERUMO CORPORATION: COMPANY SNAPSHOT (2021)
    • 10.1.5 PENUMBRA, INC.
    • TABLE 204 PENUMBRA, INC.: BUSINESS OVERVIEW
    • FIGURE 33 PENUMBRA, INC.: COMPANY SNAPSHOT (2022)
    • 10.1.6 MICROPORT SCIENTIFIC CORPORATION
    • TABLE 205 MICROPORT SCIENTIFIC CORPORATION: BUSINESS OVERVIEW
    • FIGURE 34 MICROPORT SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2022)
    • 10.1.7 BALT
    • TABLE 206 BALT: BUSINESS OVERVIEW
    • 10.1.8 KANEKA CORPORATION
    • TABLE 207 KANEKA CORPORATION: BUSINESS OVERVIEW
    • FIGURE 35 KANEKA CORPORATION: COMPANY SNAPSHOT (2022)
    • TABLE 208 PRODUCT LAUNCHES
    • 10.1.9 PHENOX GMBH
    • TABLE 209 PHENOX GMBH: BUSINESS OVERVIEW
    • 10.1.10 ASAHI INTECC CO., LTD
    • TABLE 210 ASAHI INTECC CO., LTD.: BUSINESS OVERVIEW
    • FIGURE 36 ASAHI INTECC: COMPANY SNAPSHOT (2022)
    • 10.1.11 PERFLOW MEDICAL LTD.
    • TABLE 211 PERFLOW MEDICAL LTD.: BUSINESS OVERVIEW
    • 10.1.12 RAPID MEDICAL
    • TABLE 212 RAPID MEDICAL: BUSINESS OVERVIEW
    • 10.1.13 CERUS ENDOVASCULAR INC.
    • TABLE 213 CERUS ENDOVASCULAR INC.: BUSINESS OVERVIEW
    • 10.1.14 ACANDIS GMBH
    • TABLE 214 ACANDIS GMBH: BUSINESS OVERVIEW
    • TABLE 215 ACANDIS GMBH: PRODUCTS OFFERED
    • 10.1.15 EVASC
    • TABLE 216 EVASC: BUSINESS OVERVIEW
    • 10.1.16 SENSOME
    • TABLE 217 SENSOME: BUSINESS OVERVIEW
    • 10.1.17 LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD.
    • TABLE 218 LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD.: BUSINESS OVERVIEW
    • FIGURE 37 LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD: COMPANY SNAPSHOT (2021)
    • 10.1.18 IMPERATIVE CARE
    • TABLE 219 IMPERATIVE CARE: BUSINESS OVERVIEW
    • TABLE 220 IMPERATIVE CARE: PRODUCT LAUNCHES AND APPROVALS
    • 10.1.19 MEDIKIT CO., LTD.
    • TABLE 221 MEDIKIT CO., LTD.: BUSINESS OVERVIEW
    • 10.1.20 ZYLOX-TONBRIDGE MEDICAL CO., LTD.
    • TABLE 222 ZYLOX-TONBRIDGE MEDICAL CO., LTD.: BUSINESS OVERVIEW
    • FIGURE 38 ZYLOX-TONBRIDGE MEDICAL CO., LTD.: COMPANY SNAPSHOT (2021)
    • TABLE 223 ZYLOX-TONBRIDGE MEDICAL CO., LTD.: PRODUCT LAUNCHES AND APPROVALS
  • *Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
  • 10.2 OTHER PLAYERS
    • 10.2.1 SILK ROAD MEDICAL, INC.
    • 10.2.2 ARTIO MEDICAL, INC.
    • 10.2.3 IVASCULAR
    • 10.2.4 OXFORDENDOVASCULAR
    • 10.2.5 NEUROVASC TECHNOLOGIES, INC.

11 APPENDIX

  • 11.1 DISCUSSION GUIDE
  • 11.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 11.3 CUSTOMIZATION OPTIONS
  • 11.4 RELATED REPORTS
  • 11.5 AUTHOR DETAILS
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제